Standard-of-care SARS-CoV-2 treatment — Competitive Intelligence Brief

Standard-of-care SARS-CoV-2 treatment (Standard-of-care SARS-CoV-2 treatment) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide analog. Area: Infectious Diseases.

phase 3 Nucleotide analog Infectious Diseases Small molecule

Target snapshot

Standard-of-care SARS-CoV-2 treatment (Standard-of-care SARS-CoV-2 treatment) — Chita State Regional Clinical Hospital Number 1. Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard-of-care SARS-CoV-2 treatment TARGET	Standard-of-care SARS-CoV-2 treatment	Chita State Regional Clinical Hospital Number 1	phase 3	Nucleotide analog
Veklury	remdesivir	Gilead Sciences	marketed	Nucleotide analog RNA polymerase inhibitor	SARS-CoV-2 RNA polymerase	2020-01-01
REMDESIVIR	REMDESIVIR		marketed	SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]		2020-01-01
Sofosbuvir Oral Product	Sofosbuvir Oral Product	MTI University	marketed	Nucleotide analog NS5B polymerase inhibitor	HCV NS5B RNA-dependent RNA polymerase
Nirmatrelvir/ritonavir + remdesivir	Nirmatrelvir/ritonavir + remdesivir	UMC Utrecht	phase 3	Antiviral combination (protease inhibitor + nucleotide analog)	SARS-CoV-2 3CL protease; SARS-CoV-2 RNA-dependent RNA polymerase
Cidofovir intravenous	Cidofovir intravenous	Johns Hopkins Bloomberg School of Public Health	phase 3	Nucleotide analog antiviral	Viral DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide analog class)

1. Chita State Regional Clinical Hospital Number 1 · 1 drug in this class